Wednesday, November 18, 2026
  • Home
  • About us
  • Privacy policy
  • Advertise with us
  • Contact us
Fii News Logo
No Result
View All Result
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
  • ASEANFastest Growing
Newsletter
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
  • ASEANFastest Growing
Fiinews
No Result
View All Result
Home Projects

Medivir forms partnership with GVK BIO

Fiinews by Fiinews
June 18, 2015
in Projects, Technology
Reading Time: 2 mins read
A A
0
0
SHARES
12
VIEWS
LinkedinShare on Twitter

Medivir AB has formed a partnership with GVK Biosciences Private Ltd. (GVK BIO) of Hyderabad in India, designed to deliver enhanced efficiency and quality within its portfolio of research projects while over time reducing overall research costs and enhancing future cost flexibility.
It is reorganization within its Discovery Research department, increasing its focus within the core areas of oncology and infectious diseases.
To ensure that its operations are run as efficiently as possible, Medivir has conducted a review of its Discovery Research operations. While committed to maintaining the current size of its discovery portfolio to deliver a constant flow of candidate drugs into its development pipeline, it has identified the opportunity to improve quality and efficiency through partnership with GVK BIO.
The partnership will consolidate and strengthen all current out-sourced synthetic chemistry in a single facility at GVK BIO’s Integrated Discovery Research Campus, where an addition of approximately 20 scientific staff will further accelerate the synthesis and testing of compounds.
The company has also decided to exit the neuropathic pain area, following adverse findings in non-clinical safety studies of MIV-247, its cathepsin S inhibitor being developed for neuropathic pain. Development of this program has been terminated and future drug discovery efforts will be focused in the core areas of oncology and infectious diseases.
As a result of the changes described above, around ten scientific staff at Medivir facilities in the UK and Sweden will be made redundant.


“We continue to assess all aspects of the productivity and cost-effectiveness of our businesses in order to drive innovation and maximize share-holder value” said Niklas Prager, Medivir CEO. “This reorganization and resource optimization will improve efficiency and enhance our ability to deliver well-differentiated candidate drugs into our development pipeline while over time reducing overall research costs and improving cost flexibility, and we look forward to a productive partnership with our colleagues at GVK BIO”.
“We are excited about GVK BIO’s partnership with Medivir. Medivir chose GVK BIO over several other CROs on the basis of its scientific strength and its ability to perform Integrated Research with Chemistry and Biology. We look forward to delivering significant value to Medivir shareholders and to a productive partnership” said Manni Kantipudi, CEO, GVK BIO
Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 08.30 CET on 16 June 2015.
The Nasdaq Stockholm Mid Cap List Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology.

fii-news.com

ShareTweetShare

Related Posts

DataSwitch
Technology

Tech: DataSwitch’s Mathi automates data mapping

by Fiinews
November 18, 2026
0
25

Viswanathan says legacy tools move data; DataSwitch automates data decisions Delaware-based DataSwitch says its newly launched Mathi, the AI-powered judgment...

MRPL
Projects

Project: PM dedicates Bengaluru terminal to nation

by Fiinews
November 16, 2026
0
21

MRPL has dedicated ethanol and biodiesel storage and blending infrastructure Prime Minister Narendra Modi has dedicated to the nation Mangalore...

SIH-SMU

Tech: Joshi’s call “think beyond boundaries”

November 16, 2026
31
PIB

Tech: India-Italy implemented 150+ joint projects

November 16, 2026
21
SFO

Tech: CSL-SFO produced Laser Arc Welding

November 14, 2026
18
STTGDC

Tech: STTGDC adds IT load capacity at Noida

November 14, 2026
20
SBI YONO

Recent News

  • Market: Urban consumers prefer electric mobility
  • Invest: HZL to double production to 2 mtpa
  • Market: Rootstock expands in India through Conserve
  • Market: HGS-Rackspace to grow in high-value GCCs
  • Tech: DataSwitch’s Mathi automates data mapping

Pages

  • About US
  • ADVERTISE ON FIINEWS.COM
  • CONTACT US
  • EVENTS
  • FII-NEWS.COM PDF ARCHIVE
  • Home
  • News
  • PRIVACY POLICY
  • About
  • Advertise
  • Careers
  • Contact us

© 2026 FIINEWS - Design and developed by 7clicksmedia.

No Result
View All Result
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
  • ASEAN

© 2026 FIINEWS - Design and developed by 7clicksmedia.